Annals of Oncology 13:539-545, 2002
© 2002 European Society for Medical Oncology
Original Paper |
A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer
1University of Chicago Medical Center, Chicago, IL; 2Ohio State University, Columbus, OH, USA
Received 3 September 2001; revised 6 November 2001; accepted 22 November 2001.
Background
Chemorefractory small-cell lung cancer (SCLC) is defined as disease that progresses during primary therapy or within 3 months of completion of primary therapy. Patients with chemorefractory SCLC have a very poor prognosis, and no treatment has been shown to be of significant clinical benefit. Elevated expression of Bcl-2 is found in the majority of SCLCs and has been associated with therapeutic resistance. Suppression of Bcl-2 levels through the use of G3139, an antisense oligonucleotide complementary to the mRNA encoding Bcl-2, might increase the antitumor efficacy of cytotoxic therapy.
Patients and methods
Twelve patients with chemorefractory SCLC participated in this pilot trial of paclitaxel combined with G3139. G3139 was given by continuous i.v. infusion over 7 days at a fixed dose of 3 mg/kg/day. Paclitaxel dose was initially 175 mg/m2 on day 6, but was decreased to 150 mg/m2 due to myelosuppression observed in two of the three patients treated in the first dose cohort.
Results
The combination of paclitaxel at 150 mg/m2 and G3139 at 3 mg/kg/day was found to be feasible and well tolerated. No objective responses were observed, but two patients had stable disease, one remaining stable on therapy for >30 weeks. Plasma G3139 levels were determined, and were found to be highest in the patient with prolonged stable disease, suggesting that individual variation in metabolism and clearance of the antisense oligonucleotide may influence activity.
Conclusions
This study demonstrates that G3139 can be combined with paclitaxel in a cytotoxic dose range, and suggests that a similar combination be tested for activity in the context of chemoresponsive disease.
Key words: apoptosis, chemoresistance, phosphorothioate, translational inhibition
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. L. Moulder, W. F. Symmans, D. J. Booser, T. L. Madden, C. Lipsanen, L. Yuan, A. M. Brewster, M. Cristofanilli, K. K. Hunt, T. A. Buchholz, et al. Phase I/II Study of G3139 (Bcl-2 Antisense Oligonucleotide) in Combination with Doxorubicin and Docetaxel in Breast Cancer Clin. Cancer Res., December 1, 2008; 14(23): 7909 - 7916. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Rudin, R. Salgia, X. Wang, L. D. Hodgson, G. A. Masters, M. Green, and E. E. Vokes Randomized Phase II Study of Carboplatin and Etoposide With or Without the bcl-2 Antisense Oligonucleotide Oblimersen for Extensive-Stage Small-Cell Lung Cancer: CALGB 30103 J. Clin. Oncol., February 20, 2008; 26(6): 870 - 876. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. E. Johnson, C. M. Rudin, and R. Salgia Novel and Targeted Agents for Small Cell Lung Cancer ASCO Educational Book, January 1, 2008; 2008(1): 363 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. K. Rowinsky Targeted Induction of Apoptosis in Cancer Management: The Emerging Role of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Activating Agents J. Clin. Oncol., December 20, 2005; 23(36): 9394 - 9407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tiseo, L. Boni, and A. Ardizzoni Platinum-Based Versus Non-Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Does Cisplatin Versus Carboplatin Make a Difference? J. Clin. Oncol., September 1, 2005; 23(25): 6276 - 6277. [Full Text] [PDF]
|
|
|
|
 |
|
 M Ocker, D Neureiter, M Lueders, S Zopf, M Ganslmayer, E G Hahn, C Herold, and D Schuppan Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer Gut, September 1, 2005; 54(9): 1298 - 1308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Besse, J. C. Soria, and T. Le Chevalier Front-line doublets in advanced non-small cell lung cancer: The golden age for second line chemotherapy Ann. Onc., July 1, 2005; 16(7): 997 - 998. [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Andersen, I. M. Svane, P. Kvistborg, O. J. Nielsen, E. Balslev, S. Reker, J. C. Becker, and P. t. Straten Immunogenicity of Bcl-2 in patients with cancer Blood, January 15, 2005; 105(2): 728 - 734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Hu, G. Bebb, S. Tan, R. Ng, H. Yan, J. R. Sartor, L. D. Mayer, and M. B. Bally Antitumor Efficacy of Oblimersen Bcl-2 Antisense Oligonucleotide Alone and in Combination with Vinorelbine in Xenograft Models of Human Non-Small Cell Lung Cancer Clin. Cancer Res., November 15, 2004; 10(22): 7662 - 7670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. A. Barvaux, P. Lorigan, M. Ranson, A. M. Gillum, R. S. McElhinney, T. B. H. McMurry, and G. P. Margison Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase Mol. Cancer Ther., October 1, 2004; 3(10): 1215 - 1220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Kerr A word in your ear: the 2004 Annals of Oncology prizes Ann. Onc., September 1, 2004; 15(9): 1303 - 1304. [Full Text] [PDF]
|
|
|
|
|
|
J. Marshall, H. Chen, D. Yang, M. Figueira, K. B. Bouker, Y. Ling, M. Lippman, S. R. Frankel, and D. F. Hayes A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors Ann. Onc., August 1, 2004; 15(8): 1274 - 1283. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Rudin, M. Kozloff, P. C. Hoffman, M. J. Edelman, R. Karnauskas, R. Tomek, L. Szeto, and E. E. Vokes Phase I Study of G3139, a bcl-2 Antisense Oligonucleotide, Combined With Carboplatin and Etoposide in Patients With Small-Cell Lung Cancer J. Clin. Oncol., March 15, 2004; 22(6): 1110 - 1117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tauchi, M. Sumi, A. Nakajima, G. Sashida, T. Shimamoto, and K. Ohyashiki BCL-2 Antisense Oligonucleotide Genasense Is Active against Imatinib-resistant BCR-ABL-positive Cells Clin. Cancer Res., September 15, 2003; 9(11): 4267 - 4273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Shabbits, Y. Hu, and L. D. Mayer Tumor Chemosensitization Strategies Based on Apoptosis Manipulations Mol. Cancer Ther., August 1, 2003; 2(8): 805 - 813. [Full Text] [PDF]
|
|
|
|
|
|
G. Marcucci, J. C. Byrd, G. Dai, M. I. Klisovic, P. J. Kourlas, D. C. Young, S. R. Cataland, D. B. Fisher, D. Lucas, K. K. Chan, et al. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia Blood, January 15, 2003; 101(2): 425 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Ciardiello and G. Tortora Inhibition of bcl-2 as cancer therapy Ann. Onc., April 1, 2002; 13(4): 501 - 502. [Full Text] [PDF]
|
|